| Identification | Back Directory | [Name]
GSK-2593074A) | [CAS]
1337531-06-2 | [Synonyms]
GSK'074
GSK-2593074A)
GSK2593074A
(GSK'074
GSK2593074A,GSK-2593074A
Ethanone, 1-[5-[4-amino-7-(1-methyl-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydro-1H-indol-1-yl]-2-phenyl- | [Molecular Formula]
C27H23N5OS | [MOL File]
1337531-06-2.mol | [Molecular Weight]
465.57 |
| Chemical Properties | Back Directory | [Boiling point ]
807.6±65.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 41.67 mg/mL (89.50 mM; Need ultrasonic) | [form ]
Solid | [pka]
5.79±0.40(Predicted) | [color ]
Light yellow to khaki |
| Hazard Information | Back Directory | [Uses]
GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3[1]. | [in vivo]
GSK2593074A (GSK’074; 0.93 mg/kg/day; i.p. injection; 14 or 28 days) is administrated to Apoe-/- mice immediately following pump implantation. Compared to the DMSO group, GSK2593074A-treated mice show significantly alleviated aneurysm formation, reflected by a much smaller aortic dilatation (DMSO 85.39±15.76% vs GSK2593074A 36.28±5.76%; P<0.05) as well as a reduced abdominal aortic aneurysm (AAA) incidence (from 83.3 to 16.7%). GSK2593074A significantly decreases the extent of aortic expansion (DMSO 66.06±9.17% vs GSK2593074A 27.36±8.25%; P<0.05) [1]. | Animal Model: | Apoe-/- female mice (9-10 months)[1] | | Dosage: | 0.93?mg/kg/day; 200?μL | | Administration: | Daily i.p. injection; 14 or 28 days | | Result: | Inhibited aneurysm formation in mouse models of aneurysms. |
| [storage]
Store at -20°C | [References]
[1] Zhou T, et al. Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019 Mar 6;10(3):226. DOI:10.1038/s41419-019-1468-6 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|